Criteria to qualify for study: Drug used in study:
  • Phase 1a Escalation
  • Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis
  • ANC > 1.5 / PLT > 75
  • HGB > 10 in absence of transfusion and growth factors for at least 28 days /
  • ECOG 0,1 or 2
  • Relapsed of Refractory

Hemref 43 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed of Refractory Hematologic Malignancies

Criteria to qualify for study: Drug used in study:
  • Complete response (CR), partial response (PR), or stable disease (SD) to Salvage therapy prior to ASCT. High risk of residual HL post-ASCT. Excludes patients with autoimmune diseases, any condition requiring corticosteroids, wide field radiotherapy </= 28 days or limited field for Palliation </=7 days prior to starting.

BMT 24:

A Phase 2 Single Arm Study of Nivolumab as consolidation therapy after Autologous stem cell transplantation in patients with Hodgkin Lymphomas at risk of relapse of progression.